keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson hallucination

keyword
https://www.readbyqxmd.com/read/29316780/psen1-p-met233val-in-a-complex-neurodegenerative-movement-and-neuropsychiatric-disorder
#1
Silke Appel-Cresswell, Ilaria Guella, Anna Lehman, Dean Foti, Matthew J Farrer
Mutations in presenilin 1 (PSEN1) are the most common cause of autosomal dominant Alzheimer's disease. Here, we report a Canadian-Vietnamese family carrying a PSEN1 p.Met233Val mutation with an exceptionally early and severe presentation that includes a wide range of atypical symptoms, including prominent ataxia, Parkinsonism, spasticity, dystonia, action tremor, myoclonus, bulbar symptoms, seizures, hallucinations and behavioral changes. Whole-exome sequencing (WES) was performed on the affected proband after many assessments over several years proved diagnostically inconclusive...
January 11, 2018: Journal of Movement Disorders
https://www.readbyqxmd.com/read/29305687/genetics-and-treatment-response-in-parkinson-s-disease-an-update-on-pharmacogenetic-studies
#2
REVIEW
Cristina Politi, Cinzia Ciccacci, Giuseppe Novelli, Paola Borgiani
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by a progressive loss of dopamine neurons of the central nervous system. The disease determines a significant disability due to a combination of motor symptoms such as bradykinesia, rigidity and rest tremor and non-motor symptoms such as sleep disorders, hallucinations, psychosis and compulsive behaviors. The current therapies consist in combination of drugs acting to control only the symptoms of the illness by the replacement of the dopamine lost...
January 5, 2018: Neuromolecular Medicine
https://www.readbyqxmd.com/read/29261640/the-added-value-of-dynamic-18f-florbetapir-pet-in-the-assessment-of-dementia-with-lewy-bodies
#3
Diego Alfonso López Mora, Valle Camacho, Alberto Lleó, Alejandro Fernández, Ignasi Carrió
Dementia with Lewy bodies (DLB) is the most common cause of dementia after Alzheimer disease. It is often underdiagnosed because of the overlapping with Alzheimer disease symptoms. We report the F-FDG and F-florbetapir dynamic PET images (early and delay phases) of an 83-year-old woman with cognitive impairment associated with visual hallucinations and parkinsonism due to probable DLB. This image highlights that the early phases of F-florbetapir may reflect regional cerebral perfusion with a pattern very similar to that of regional glucose metabolism in DLB...
December 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29222591/dementia-with-lewy-bodies-and-parkinson-s-disease-dementia-current-concepts-and-controversies
#4
REVIEW
Kurt A Jellinger
Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although sharing many clinical, neurochemical and morphological features, according to DSM-5, are two entities of major neurocognitive disorders with Lewy bodies of unknown etiology. Despite considerable clinical overlap, their diagnosis is based on an arbitrary distinction between the time of onset of motor and cognitive symptoms: dementia often preceding parkinsonism in DLB and onset of cognitive impairment after onset of motor symptoms in PDD...
December 8, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29193464/functional-connectivity-in-dementia-with-lewy-bodies-a-within-and-between-network-analysis
#5
Julia Schumacher, Luis R Peraza, Michael Firbank, Alan J Thomas, Marcus Kaiser, Peter Gallagher, John T O'Brien, Andrew M Blamire, John-Paul Taylor
Dementia with Lewy bodies (DLB) is a common form of dementia and is characterized by cognitive fluctuations, visual hallucinations, and Parkinsonism. The phenotypic expression of the disease may, in part, relate to alterations in functional connectivity within and between brain networks. This resting-state study sought to clarify this in DLB, how networks differed from Alzheimer's disease (AD), and whether they were related to clinical symptoms in DLB. Resting-state networks were estimated using independent component analysis...
November 29, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/29166782/screening-for-the-c9orf72-repeat-expansion-in-a-greek-frontotemporal-dementia-cohort
#6
Chrisoula Kartanou, Georgia Karadima, Georgios Koutsis, Marianthi Breza, Sokratis G Papageorgiou, George P Paraskevas, Elisabeth Kapaki, Marios Panas
The C9orf72 repeat expansion is a common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in European populations. A previous study has reported a high frequency of the expansion in Greek ALS. However, no data have been reported on the frequency of the expansion in Greek FTD. Currently, we investigated the frequency of the C9orfF72 expansion in a well-characterized cohort of 64 Greek FTD patients. We detected the C9orf72 repeat expansion in 9.3% of cases. Overall, 27.7% of familial and 2...
November 23, 2017: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
https://www.readbyqxmd.com/read/29160144/parkinson-s-disease-psychosis-presentation-diagnosis-and-management
#7
Ruth B Schneider, Julia Iourinets, Irene H Richard
Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions. PDP is associated with reduced function and quality of life. The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia...
November 21, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29143692/non-pharmacological-interventions-for-lewy-body-dementia-a-systematic-review
#8
Michael H Connors, Lena Quinto, Ian McKeith, Henry Brodaty, Louise Allan, Claire Bamford, Alan Thomas, John-Paul Taylor, John T O'Brien
Lewy body dementia (consisting of dementia with Lewy bodies and Parkinson's disease dementia) is a common neurodegenerative disease characterised by visual hallucinations, fluctuating attention, motor disturbances, falls, and sensitivity to antipsychotics. This combination of features presents challenges for pharmacological management. Given this, we sought to review evidence for non-pharmacological interventions with patients with Lewy body dementia and their carers. Bibliographic databases were searched using a wide range of search terms and no restrictions were placed on study design, language, or clinical setting...
November 16, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/29120562/be-vigilant-for-dementia-in-parkinson%C3%A2-s-disease
#9
Flavia Niccolini, Konstantinos Diamantopoulos, Stelios Kiosses, Marios Politis
It is estimated that up to 80% of patients with Parkinson's disease will eventually develop cognitive impairment over the course of their illness. Even at the time of diagnosis, cognitive impairment has been reported in 20-25% of patients. Commonly affected cognitive domains are executive function, visuospatial ability and attention control. In addition, patients with Parkinson's disease dementia may present with deficits in language function and verbal memory. Psychosis may occur in approximately 40% of patients with Parkinson's disease, and is associated with an increased risk of developing cognitive impairment...
May 2017: Practitioner
https://www.readbyqxmd.com/read/29102236/rem-sleep-behavior-disorder-portends-poor-prognosis-in-parkinson-s-disease-a-systematic-review
#10
REVIEW
Yoon Kim, Young Eun Kim, Eun Ok Park, Chae Won Shin, Han-Joon Kim, Beomseok Jeon
REM sleep behavior disorder (RBD) is a parasomnia wherein a loss of REM sleep atonia manifests as dream-enactment, often violent. Aside from its significance as a predictor of PD, RBD in PD may imply more than merely screaming at night and experiencing sleep fragmentation. To probe its significance as a prognostic factor in PD, we performed a systematic literature review. Analysis of prospective studies reveals baseline RBD confers a higher risk of developing dementia and hallucinations. In cross-sectional studies, RBD is associated with the non-tremor predominant motor phenotype and autonomic dysfunction...
October 25, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29098976/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#11
Leslie Citrome, James C Norton, Kathy Chi-Burris, George Demos
OBJECTIVE: Our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP), using the metrics of number needed to treat (NNT) and number needed to harm (NNH). METHODS: Categorical efficacy and tolerability data were extracted from the clinical trial databases of the double-blind placebo-controlled studies of pimavanserin in persons with PDP...
November 3, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29091972/progression-of-parkinson-s-disease-is-associated-with-gut-dysbiosis-two-year-follow-up-study
#12
Tomomi Minato, Tetsuya Maeda, Yoshiro Fujisawa, Hirokazu Tsuji, Koji Nomoto, Kinji Ohno, Masaaki Hirayama
BACKGROUND: We previously reported gut dysbiosis in patients with Parkinson's disease (PD). OBJECTIVE: The aim of this study is to examine whether gut dysbiosis correlates with the progression of PD. METHODS: We examined changes in gut microbiota and demographic features in 2 years in 36 PD patients. RESULTS: A change of total UPDRS scores in 2 years was predicted by the counts of Bifidobacterium and Atopobium cluster at year 0 with a correlation coefficient of 0...
2017: PloS One
https://www.readbyqxmd.com/read/29059136/successful-use-of-escitalopram-for-the-treatment-of-visual-hallucinations-in-patients-with-parkinson-disease
#13
Joseph Bergman, Paul P Lerner, Shmuel Sokolik, Vladimir Lerner, Anatoly Kreinin, Chanoch Miodownik
INTRODUCTION: Patients with Parkinson disease (PD) frequently experience visual hallucinations (VH). Visual hallucinations are most often viewed as an adverse effect of antiparkinsonian treatment. Possible treatments for this disturbance include a reduction of antiparkinsonian medications, adding atypical antipsychotics, or cholinesterase inhibitors. Some studies demonstrated that selective serotonin reuptake inhibitors may be an optional treatment for patients experiencing psychosis or agitation in dementia...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059132/medical-cannabis-in-parkinson-disease-real-life-patients-experience
#14
Yacov Balash, Lihi Bar-Lev Schleider, Amos D Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, Tanya Gurevich
BACKGROUND: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series. OBJECTIVE: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms of Parkinson disease (PD) and its adverse effects in patients treated for at least 3 months. METHODS: The survey used telephone interviews using a structured questionnaire based on subjective global impressions of change for various parkinsonian symptoms and yes/no questions on adverse effects...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29047301/pimavanserin-novel-pharmacotherapy-for-parkinson-s-disease-psychosis
#15
Zeyad T Sahli, Frank I Tarazi
Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Areas covered: This review focuses on the preclinical discovery of pimavanserin. It analyzes the pharmacological, behavioral and molecular mechanisms of pimavanserin and their contribution to the therapeutic advantages of the drug as reported in published preclinical and clinical studies, press releases and product labels. Expert opinion: Pimavanserin exhibits a unique pharmacological profile with nanomolar affinity at serotonin 5-HT2A and 5-HT2C receptors...
January 2018: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29038946/cognitive-and-behavioral-disorders-in-parkinson-s-disease-an-update-ii-behavioral-disorders
#16
Luigi Trojano, Costanza Papagno
Patients with Parkinson's disease (PD) can experience several behavioral symptoms, such as apathy, agitation, hypersexuality, stereotypic movements, pathological gambling, abuse of antiparkinsonian drugs, and REM sleep behavioral disorders. Psychoses and hallucinations, depression and anxiety disorders, and difficulties in recognizing and experiencing emotions also impair behavior and can cause severe psychosocial problems in patients with PD. Symptoms can be present since early stages of the disease, sometimes even before the appearance of classical motor symptoms, likely in relation to dopamine depletion in basal ganglia and/or to dysfunctions of other neurotrasmitter systems, and others can develop later, in some cases in relation to dopaminergic treatment...
October 16, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/29037340/-neuropsychiatry-of-movement-disorders
#17
Juan Manuel Orjuela-Rojas, Gustavo Adolfo Barrios Vincos, Melisa Alejandra Martínez Gallego
Movement disorders can be defined as neurological syndromes presenting with excessive or diminished automatic or voluntary movements not related to weakness or spasticity. Both Parkinson's disease (PD) and Huntington's disease (HD) are well-known examples of these syndromes. The high prevalence of comorbid psychiatric symptoms like depression, anxiety, obsessive-compulsive symptoms, hallucinations, delusions, impulsivity, sleep disorders, apathy and cognitive impairment mean that these conditions must be regarded as neuropsychiatric diseases...
October 2017: Revista Colombiana de Psiquiatría
https://www.readbyqxmd.com/read/29032012/continuous-subcutaneous-apomorphine-infusion-in-parkinson-s-disease-patients-with-cognitive-dysfunction-a-retrospective-long-term-follow-up-study
#18
Robbert W K Borgemeester, Teus van Laar
INTRODUCTION: Continuous apomorphine infusion (CAI) is an advanced therapy in fluctuating Parkinson's disease (PD). The use of CAI is controversial in PD patients with cognitive dysfunction including visual hallucinations (VHs), and orthostatic hypotension (OH). This study was set-up to analyze the effectiveness and safety of CAI in elderly PD patients with cognitive dysfunction. METHODS: This new-user cohort study identified fluctuating PD patients who started CAI treatment at the rehabilitation unit of Parkinson Expertise Center (RU-PEC) Groningen, from November 2004 until 2016...
September 29, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28993094/characterization-of-diplopia-in-non-demented-patients-with-parkinson-s-disease
#19
Katharina A Schindlbeck, Shideh Schönfeld, Wanda Naumann, David J Friedrich, André Maier, Charlotte Rewitzer, Fabian Klostermann, Frank Marzinzik
INTRODUCTION: Although diplopia is considered a frequent symptom of Parkinson's disease (PD), little is known about its clinical manifestation, associated mechanisms and treatment. Here we characterized binocular diplopia in non-demented PD patients in an interdisciplinary setting. METHODS: PD patients were prospectively screened for diplopia, visual hallucinations, problems with spatial perception, contrast sensitivity, presence of blurred vision, and history of ophthalmological comorbidities via interview...
September 29, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28991698/pitx3-genotype-and-risk-of-dementia-in-parkinson-s-disease-a-population-based-study
#20
David Bäckström, Magdalena Eriksson Domellöf, Gabriel Granåsen, Jan Linder, Sofia Mayans, Eva Elgh, Susanna Jakobson Mo, Lars Forsgren
Dementia is a devastating manifestation of Parkinson's disease (PD). This study investigates whether a common polymorphism in the PITX3 gene (rs2281983), which is of importance for the function of dopaminergic neurons, affects the risk of developing dementia in PD and whether it affects dopamine transporter (DAT) uptake. We PITX3 genotyped 133 patients with new-onset, idiopathic PD, participating in a population-based study in Sweden. Patients were followed prospectively during 6-11years with extensive investigations, including neuropsychology and DAT-imaging with (123)I FP-CIT...
October 15, 2017: Journal of the Neurological Sciences
keyword
keyword
48244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"